Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Galapagos : Servier Knee Osteoarthritis Trial Fails to Meet Primary, Secondary Endpoints

10/15/2020 | 05:03pm EST

By Kimberly Chin

Galapagos NV and Servier said Thursday that their Phase 2 study for a treatment for patients with knee osteoarthritis didn't meet its primary objective.

The double-blind, placebo-controlled study of GLPG1972/S201086 looked at the efficacy of three different once-daily doses on patients in reducing cartilage loss over a 52-week period. The cartilage thickness in patients showed no statistically significant difference between the placebo and any of the treated groups, the companies said.

The study also failed to meet secondary endpoints, showing no significant difference in treated patients compared with the placebo group, the companies said.

Write to Kimberly Chin at kimberly.chin@wsj.com

(END) Dow Jones Newswires

10-15-20 1702ET

All news about GALAPAGOS NV
11/23GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
11/23GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
11/09GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
11/09GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
11/09First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
GL
11/09OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent ..
AQ
11/05GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
11/05GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
11/05OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhi..
GL
11/05GALAPAGOS : reports Q3 2020 results
AQ
More news
Financials
Sales 2020 526 M 626 M 626 M
Net income 2020 -316 M -376 M -376 M
Net cash 2020 3 596 M 4 282 M 4 282 M
P/E ratio 2020 -23,4x
Yield 2020 -
Capitalization 6 642 M 7 910 M 7 908 M
EV / Sales 2020 5,79x
EV / Sales 2021 6,01x
Nbr of Employees 1 407
Free-Float 74,4%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 127,11 €
Last Close Price 101,65 €
Spread / Highest target 57,4%
Spread / Average Target 25,0%
Spread / Lowest Target 3,30%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Operating & Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV-45.50%7 910
LONZA GROUP AG55.66%44 931
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.32%39 870
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832